Results 121 to 130 of about 1,844 (180)

Response to the letter to the editor concerning: 'catastrophic apical ballooning in obstructive hypertrophic cardiomyopathy patient treated with mavacamten: case report'. [PDF]

Eur Heart J Case Rep
De Roeck F, Gevaert AB, Van Craenenbroeck E.   +2 more
europepmc   +1 more source

Editorial: Hypertrophic Cardiomyopathy and Precision Medicine in Cardiovascular Disease. [PDF]

Med Sci Monit
Parums DV.
europepmc   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects. [PDF]

Drug Des Devel Ther
Hou L, Lin B, Ji X, Huang A.
europepmc   +1 more source

Cardiogenic Shock in Hypertrophic Cardiomyopathy Treated With Mavacamten and Clarithromycin. [PDF]

JACC Case Rep
Alabdaljabar MS, Desai M, Geske JB.
europepmc   +1 more source

Mavacamten effectively reduces > 100 mmHg left ventricular outflow tract gradients As early as one week of treatment in obstructive hypertrophic cardiomyopathy [PDF]

Boda Krisztina, Borbás János, Kormányos Árpád, Nagy Viktória, Pintér Jenő Antal, Polestyuk Bianka Petra, Pálinkás Attila, Rácz Gergely, Schvartz Noémi, Sepp Róbert, Szili-Török Tamás, Szűcsborus Tamás, Takács Hedvig, Vidács Dániel László   +13 more
core   +1 more source

Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology. [PDF]

Card Fail Rev
Li-Wen Chu E, Seung Kim D, Masri A.
europepmc   +1 more source

Net health benefit of mavacamten for the treatment of Chinese patients with obstructive hypertrophic cardiomyopathy: a model-based economic evaluation. [PDF]

Front Pharmacol
Bao H, Jia Y, Wang X, Hurst M, Cheah Z, Ho M, Xuan J.   +6 more
europepmc   +1 more source

Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

, 2020
C. Y., Ho, Heitner, S. B., Jacoby, D., Lester, S. J., Olivotto, I., Roe, M., Sehnert, A. J., Waldman, C. B., Wang, A., Zhang, D.   +9 more
core   +1 more source

Real‐world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population [PDF]

Biagioni, Giulia, Gabrielli, Domenico, Insinna, Eleonora, Marchi, Alberto, Olivotto, Iacopo, Patti, Giuseppe, Pieroni, Maurizio   +6 more
core   +1 more source

Treatment of Symptomatic Mid-Cavitary Obstruction Hypertrophic Cardiomyopathy With Mavacamten. [PDF]

JACC Case Rep
Zhang X, Ye Q, Chen S, Lu H, Ji X.
europepmc   +1 more source